Loading…
Employees: 1,180
Size COLTENE (CLTN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $361M, the 153rd largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 49.30 on 6 Nov 2026.
Performance Over six months the shares gained 2.7%, against -11.2% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 2.5% over the last twelve months (peer median +11.5%); the operating margin is 7.9% (peer median 2.6%).
Valuation It trades at 25.9× forward earnings against a peer median of 15.8× (4th most expensive of 11).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is +1 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 6.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 5 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 235M | CHF 240M | CHF 250M | CHF 243M | CHF 267M |
| Revenue growth | — | -4% | +3% | -9% | — |
| Gross profit | CHF 58.9M | CHF 61.5M | CHF 67.7M | CHF 59.7M | CHF 78.3M |
| EBITDA | CHF 26.0M | CHF 27.7M | CHF 33.7M | CHF 26.6M | CHF 41.7M |
| Net income | CHF 14.7M | CHF 14.9M | CHF 20.5M | CHF 11.9M | CHF 26.0M |
| Free cash flow | CHF 14.5M | CHF 9.17M | CHF 23.8M | CHF 19.1M | CHF 17.9M |
| Capital expenditure | CHF 6.63M | CHF 6.08M | CHF 5.75M | CHF 8.68M | CHF 8.32M |
| Total debt | n/a | CHF 47.0M | CHF 40.0M | CHF 45.0M | CHF 47.1M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CLTN.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +4.0% | -7.4% | 4th highest of 21 |
| 6-month return | +2.7% | -11.2% | 7th highest of 20 |
| Distance from 52-week high | -16.4% | -41.5% | 3rd highest of 21 |
| Revenue growth (TTM) | -2.5% | +11.5% | 9th lowest of 20 |
| Operating margin | 7.9% | 2.6% | 9th highest of 20 |
| Forward P/E | 25.9× | 15.8× | 4th most expensive of 11 |
| Growth the price implies (Req g, 7 yrs) | 0.1% | -7.6% | 6th most demanding of 12 |
| Growth delivered (Del g) | -0.7% | -0.1% | 6th lowest of 12 |
| Hurdle (Req g minus delivered) | +0.8 pp | +8.7 pp | 6th least demanding of 12 |
| ROIC minus cost of capital | +6.7 pp | -5.2 pp | 7th highest of 17 |
| EV / EBITDA | 12.6× | 6.8× | 4th most expensive of 10 |
| Net debt / EBITDA | 1.3× | -3.7× | 3rd most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| COLTENE CLTN.SW | Switzerland | $361M | +3% | -2% | 8% | 25.9× | 0.1% | -0.7% |
| IVF HARTMANN VBSN.SW | Switzerland | $364M | -5% | +7% | 14% | n/a | -12.7% | -1.3% |
| Chongqing Xishan Science and Technology 688576.SS | China | $356M | -26% | -23% | -29% | 15.2× | n/a | n/a |
| Star Sports Medicine 1609.HK | Hong Kong | $367M | -76% | +23% | 37% | n/a | -13.2% | +36.8% |
| Shenzhen Bioeasy Biotechnology 300942.SZ | China | $352M | -27% | +12% | -2% | n/a | n/a | n/a |
| Embecta EMBC | United States | $351M | +70% | -8% | 26% | 3.9× | -19.9% | -0.1% |
| Mobia Medical MOBI | United States | $373M | n/a | +105% | -145% | n/a | n/a | n/a |
| ACRO Biomedical 6748.TWO | Taiwan | $347M | +129% | +45% | -178% | n/a | n/a | n/a |
| Jiangsu Apon Medical Technology 300753.SZ | China | $376M | -27% | -15% | -10% | 994.0× | 22.4% | -5.1% |
| InBody 041830.KS | South Korea | $378M | +43% | +21% | 19% | 11.4× | -7.6% | +16.9% |
| Yantai Zhenghai Bio-Tech 300653.SZ | China | $380M | -23% | -8% | 17% | 38.5× | 20.0% | +4.4% |
| BioNote 377740.KS | South Korea | $343M | -10% | +13% | 16% | 15.0× | -19.8% | -28.5% |
| Chemclin Diagnostics 688468.SS | China | $342M | -23% | -14% | 6% | n/a | 31.9% | -4.5% |
| Orchestra BioMed OBIO | United States | $341M | +41% | +986% | -181% | n/a | n/a | n/a |
| Stratec SBS.DE | Germany | $341M | +41% | -3% | 3% | 16.4× | n/a | n/a |
| Peijia Medical 9996.HK | Hong Kong | $340M | -34% | +21% | -13% | 335.5× | n/a | n/a |
| Nanjing Medlander Medical Technology 688273.SS | China | $385M | -44% | -12% | 8% | 20.0× | 39.0% | +5.2% |
| Clarity Pharmaceuticals CU6.AX | Australia | $386M | -48% | n/a | n/a | n/a | n/a | n/a |
| CapsoVision CV | United States | $336M | -11% | +15% | -217% | n/a | n/a | n/a |
| Jiangsu Nanfang Medical 603880.SS | China | $336M | +4% | -7% | -15% | n/a | 22.5% | -10.9% |
| OrbusNeich Medical 6929.HK | Hong Kong | $389M | -3% | +16% | 23% | 8.3× | -18.5% | +15.4% |